54
edits
Changes
PHAC Conflict of Interest Toolkit for Guideline Development (view source)
Revision as of 13:36, 16 April 2021
, 13:36, 16 April 2021→Examples of scales for assessing the significance of COI
Overall, one clear theme emerged from the BBE: The need for national leadership, national standards, national approaches, and national transparency to help bring Canada up to the level of COI management seen in other countries.<ref name=":5" /> A report summarizing the BBE presentations and discussions is available in both official languages using the following links:
Overall, one clear theme emerged from the BBE: The need for national leadership, national standards, national approaches, and national transparency to help bring Canada up to the level of COI management seen in other countries.<ref name=":5" /> A report summarizing the BBE presentations and discussions is available in both official languages using the following links:
[[Media: BBE COI in CPG development EN FINAL.pdf|CIHR/PHAC Best Brains Exchange (English) - Reducing and managing conflicts of interest in clinical practice guideline development: Do we need Pan-Canadian standards?]]
[[Images/0/0b/BBE COI in CPG development EN FINAL.pdf|CIHR/PHAC Best Brains Exchange (English) - Reducing and managing conflicts of interest in clinical practice guideline development: Do we need Pan-Canadian standards?]]
[[Media: BBE COI in CPG development FR FINAL.pdf|Échanges Meilleurs Cerveaux IRSC/ASPC (français) - Réduction et gestion des conflits d’intérêts dans l’élaboration de recommandations pour la pratique clinique : faut-il établir des normes pancanadiennes?]]
[[Images/e/e1/BBE COI in CPG development FR FINAL.pdf|Échanges Meilleurs Cerveaux IRSC/ASPC (français) - Réduction et gestion des conflits d’intérêts dans l’élaboration de recommandations pour la pratique clinique : faut-il établir des normes pancanadiennes?]]
Shortly after the BBE, the Canadian Medical Association Journal, one of the foremost publishers of guidelines in Canada, announced that as of 2020, all groups publishing guidelines in their journal must adhere to the GIN principles.<ref>Kelsall D. New CMAJ policy on competing interests in guidelines. CMAJ. 2019; 191(13):E350-351. </ref> Therefore it is anticipated that a key area for national leadership in this area will be to help Canadian guideline producers (within PHAC or external) in adhering to the GIN principles, and generally implementing best practices related to COI. For some groups, this may require only small shifts in their current policies and procedures, while for other groups (e.g., smaller or with less resources) this could require considerable work.
Shortly after the BBE, the Canadian Medical Association Journal, one of the foremost publishers of guidelines in Canada, announced that as of 2020, all groups publishing guidelines in their journal must adhere to the GIN principles.<ref>Kelsall D. New CMAJ policy on competing interests in guidelines. CMAJ. 2019; 191(13):E350-351. </ref> Therefore it is anticipated that a key area for national leadership in this area will be to help Canadian guideline producers (within PHAC or external) in adhering to the GIN principles, and generally implementing best practices related to COI. For some groups, this may require only small shifts in their current policies and procedures, while for other groups (e.g., smaller or with less resources) this could require considerable work.
=== Examples of disclosure of interest forms: ===
=== Examples of disclosure of interest forms: ===
* [[Media: PHAC DOI form 11Sept2020 v9.0.docx|(IN DEVELOPMENT) PHAC Dislosure of Interest Form (last updated Sept 11, 2020)]]
* [[Images/b/b2/PHAC DOI form 11Sept2020 v9.0.docx|(IN DEVELOPMENT) PHAC Dislosure of Interest Form (last updated Sept 11, 2020)]]
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form]
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form]
* [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines-form.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members]
* [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines-form.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members]
=== Examples of scales for assessing the significance of COI ===
=== Examples of scales for assessing the significance of COI ===
* [[Media: PHAC_COI_Tool_16Apr2021.xlsx|(IN DEVELOPMENT) PHAC COI Assessment Tool (last updated April 16,2021)]]
* [[Images/2/20/PHAC COI Tool 16Apr2021.xlsx|(IN DEVELOPMENT) PHAC COI Assessment Tool (last updated April 16, 2021)]]
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i13 American Thoracic Society method for evaluating significance of COI]
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i13 American Thoracic Society method for evaluating significance of COI]
* [https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf World Health Organization criteria for assessing the severity of a conflict of interest] (see p. 78)
* [https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf World Health Organization criteria for assessing the severity of a conflict of interest] (see p. 78)